• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾素-血管紧张素系统抑制剂(RASI)对牛津分类肾小管间质病变的 IgA 肾病的有益作用。

The beneficial effects of renin-angiotensin system inhibitors (RASI) on IgA nephropathy with tubulointerstitial lesions categorized by Oxford classification.

机构信息

Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjyuku-ku, 162-8666, Tokyo, Japan.

出版信息

Clin Exp Nephrol. 2019 Jun;23(6):834-840. doi: 10.1007/s10157-019-01713-w. Epub 2019 Feb 22.

DOI:10.1007/s10157-019-01713-w
PMID:30796546
Abstract

BACKGROUND

Global sclerosis has been reported as the risk factor of IgAN. In Oxford classification, global sclerosis was correlated with tubulointerstitial (T) lesions. Therefore, in patients with T lesions, renin-angiotensin system inhibitors (RASI) might be effective by decreasing glomerular hyperfiltration and hypertension. However, these beneficial effects of RASI have not been reported.

METHODS

In this retrospective cohort study, we divided 87 IgAN patients with T1/2 lesions into two groups: RASI group (n = 47, treated with RASI) and APA group (n = 40, treated with anti-platelet agents). We analyzed the background of each group, the serial changes of blood pressure and the amount of proteinuria (U-Prot), progression to end-stage renal disease, and the risk factors for progression.

RESULTS

After propensity score matching, 22 cases from each group were selected, and clinical and histological characteristics were similar. Serial changes of blood pressure had been significantly decreased in RASI group (p = 0.0029), but not in the APA group. Proteinuria was tended to decrease in RASI group, though it was not significant (1.14-0.47 g/gCre) and it was similar in APA group (0.95-0.85 g/gCre). 20 year renal survival rate was 59.5% in RASI group, whereas 21.3% in APA group (p = 0.0119). In multivariate Cox regression analysis, RASI was an independent factor to prevent from progression to ESRD (HR 5.91, p = 0.0039).

CONCLUSION

RASI has shown a significant beneficial effect on histologically advanced IgAN patients with T lesions. These results are compatible with the previous studies that reported the beneficial effects of RASI on clinically advanced IgAN patients.

摘要

背景

全球硬化已被报道为 IgAN 的危险因素。在牛津分类中,全球硬化与肾小管间质(T)病变相关。因此,在 T 病变患者中,肾素-血管紧张素系统抑制剂(RASI)可能通过降低肾小球高滤过和高血压而有效。然而,尚未报道这些 RASI 的有益效果。

方法

在这项回顾性队列研究中,我们将 87 例 T1/2 病变的 IgAN 患者分为 RASI 组(n=47,接受 RASI 治疗)和 APA 组(n=40,接受抗血小板治疗)。我们分析了每组的背景、血压的连续变化和蛋白尿(U-Prot)量、进展为终末期肾病的情况以及进展的危险因素。

结果

经过倾向评分匹配后,每组选择了 22 例病例,临床和组织学特征相似。RASI 组的血压连续变化显著降低(p=0.0029),而 APA 组则没有。RASI 组蛋白尿有下降趋势,但无统计学意义(1.14-0.47 g/gCre),而 APA 组则相似(0.95-0.85 g/gCre)。RASI 组的 20 年肾脏存活率为 59.5%,而 APA 组为 21.3%(p=0.0119)。多变量 Cox 回归分析显示,RASI 是防止进展为 ESRD 的独立因素(HR 5.91,p=0.0039)。

结论

RASI 对 T 病变的组织学进展期 IgAN 患者显示出显著的有益效果。这些结果与先前报道 RASI 对临床进展期 IgAN 患者有益的研究结果一致。

相似文献

1
The beneficial effects of renin-angiotensin system inhibitors (RASI) on IgA nephropathy with tubulointerstitial lesions categorized by Oxford classification.肾素-血管紧张素系统抑制剂(RASI)对牛津分类肾小管间质病变的 IgA 肾病的有益作用。
Clin Exp Nephrol. 2019 Jun;23(6):834-840. doi: 10.1007/s10157-019-01713-w. Epub 2019 Feb 22.
2
Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function.比较肾素-血管紧张素-醛固酮系统(RAS)抑制剂和类固醇加 RAS 抑制剂联合治疗晚期免疫球蛋白 A 肾病和肾功能受损患者。
Clin Exp Nephrol. 2012 Apr;16(2):231-7. doi: 10.1007/s10157-011-0545-7. Epub 2011 Oct 26.
3
Severity of arterial and/or arteriolar sclerosis in IgA nephropathy and the effects of renin-angiotensin system inhibitors on its prognosis.IgA 肾病的动脉和(或)小动脉硬化严重程度及其对肾素-血管紧张素系统抑制剂预后的影响。
J Pathol Clin Res. 2021 Nov;7(6):616-623. doi: 10.1002/cjp2.234. Epub 2021 Jun 29.
4
Early Renin-angiotensin System Blockade Improved Short-term and Longterm Renal Outcomes in Systemic Lupus Erythematosus Patients with Antiphospholipid-associated Nephropathy.早期肾素-血管紧张素系统阻断治疗改善抗磷脂抗体相关肾病的系统性红斑狼疮患者的短期和长期肾脏结局。
J Rheumatol. 2018 May;45(5):655-662. doi: 10.3899/jrheum.170561. Epub 2018 Feb 15.
5
Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.IgA肾病临床及形态学预后危险因素的意义:有无肾脏保护作用的对比患者组的随访研究
BMC Nephrol. 2017 Mar 14;18(1):89. doi: 10.1186/s12882-017-0499-4.
6
Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂治疗对晚期免疫球蛋白 A 肾病和肾功能受损患者的长期有益影响。
Clin Exp Nephrol. 2011 Oct;15(5):700-707. doi: 10.1007/s10157-011-0455-8. Epub 2011 May 31.
7
The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.牛津分类法在儿童 IgA 肾病中的应用与肾脏结局的相关性分析——一项回顾性队列研究。
BMC Nephrol. 2020 Jul 1;21(1):247. doi: 10.1186/s12882-020-01913-7.
8
Effects of combination therapy with renin-angiotensin system inhibitors and eicosapentaenoic acid on IgA nephropathy.肾素-血管紧张素系统抑制剂与二十碳五烯酸联合治疗对IgA肾病的影响。
Intern Med. 2013;52(2):193-9. doi: 10.2169/internalmedicine.52.8323. Epub 2013 Jan 15.
9
Urinary exosomal mRNAs as biomarkers for predicting the therapeutic effect of renin-angiotensin system inhibitors in IgA nephropathy patients.尿外泌体mRNA作为预测IgA肾病患者肾素-血管紧张素系统抑制剂治疗效果的生物标志物。
Clin Chim Acta. 2024 Jul 15;561:119750. doi: 10.1016/j.cca.2024.119750. Epub 2024 Jun 15.
10
The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.肾素-血管紧张素系统阻断对IgA肾病终末期肾病发生率的影响。
Clin Exp Nephrol. 2016 Oct;20(5):689-698. doi: 10.1007/s10157-015-1195-y. Epub 2015 Nov 12.

引用本文的文献

1
Prognostic significance of the extent of tubulointerstitial lesions in patients with IgA nephropathy.IgA肾病患者肾小管间质病变程度的预后意义
Int Urol Nephrol. 2023 Mar;55(3):671-677. doi: 10.1007/s11255-022-03286-2. Epub 2022 Sep 1.
2
Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy.评估个性化治疗对免疫球蛋白A肾病患者疗效的随机临床研究。
Clin Kidney J. 2021 Dec 15;15(5):895-902. doi: 10.1093/ckj/sfab263. eCollection 2022 May.
3
Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies.

本文引用的文献

1
New insight into the management of IgA nephropathy.IgA肾病管理的新见解。
Clin Exp Nephrol. 2018 Dec;22(6):1442-1443. doi: 10.1007/s10157-018-1555-5. Epub 2018 Mar 14.
2
The Japanese Histologic Classification and T-score in the Oxford Classification system could predict renal outcome in Japanese IgA nephropathy patients.日本组织学分类和牛津分类系统中的T评分可预测日本IgA肾病患者的肾脏预后。
Clin Exp Nephrol. 2017 Dec;21(6):986-994. doi: 10.1007/s10157-017-1393-x. Epub 2017 Mar 27.
3
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.
黏膜免疫反应、感染和肠道微生物组如何影响 IgA 肾病和未来的治疗方法。
Theranostics. 2020 Sep 15;10(25):11462-11478. doi: 10.7150/thno.49778. eCollection 2020.
4
The impact of tonsillectomy combined with steroid pulse therapy in patients with advanced IgA nephropathy and impaired renal function.扁桃体切除术联合类固醇脉冲疗法对肾功能受损的晚期 IgA 肾病患者的影响。
Clin Exp Nephrol. 2020 Apr;24(4):295-306. doi: 10.1007/s10157-019-01828-0. Epub 2019 Dec 16.
牛津 IgA 肾病分类 2016 年更新:IgA 肾病分类工作组的报告。
Kidney Int. 2017 May;91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22.
4
Reproducibility for pathological prognostic parameters of the Oxford classification of IgA nephropathy: a Japanese cohort study of the Ministry of Health, Labor and Welfare.IgA肾病牛津分类法病理预后参数的可重复性:日本厚生劳动省队列研究
Clin Exp Nephrol. 2017 Feb;21(1):92-96. doi: 10.1007/s10157-016-1258-8. Epub 2016 Mar 24.
5
Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy.通过治疗干预降低蛋白尿可改善老年IgA肾病患者的肾脏预后。
Clin Exp Nephrol. 2016 Dec;20(6):910-917. doi: 10.1007/s10157-016-1239-y. Epub 2016 Feb 1.
6
The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.肾素-血管紧张素系统阻断对IgA肾病终末期肾病发生率的影响。
Clin Exp Nephrol. 2016 Oct;20(5):689-698. doi: 10.1007/s10157-015-1195-y. Epub 2015 Nov 12.
7
Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis.IgA 肾病牛津分类评估:系统评价和荟萃分析。
Am J Kidney Dis. 2013 Nov;62(5):891-9. doi: 10.1053/j.ajkd.2013.04.021. Epub 2013 Jun 29.
8
Comparison of steroids and angiotensin receptor blockers for patients with advanced IgA nephropathy and impaired renal function.比较晚期 IgA 肾病和肾功能受损患者使用类固醇和血管紧张素受体阻滞剂。
Am J Nephrol. 2011;34(3):233-40. doi: 10.1159/000330189. Epub 2011 Jul 22.
9
Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂治疗对晚期免疫球蛋白 A 肾病和肾功能受损患者的长期有益影响。
Clin Exp Nephrol. 2011 Oct;15(5):700-707. doi: 10.1007/s10157-011-0455-8. Epub 2011 May 31.
10
The incidence of primary glomerulonephritis worldwide: a systematic review of the literature.原发性肾小球肾炎的全球发病率:文献系统综述。
Nephrol Dial Transplant. 2011 Feb;26(2):414-30. doi: 10.1093/ndt/gfq665. Epub 2010 Nov 10.